8.3.3 Hormone antagonists
| Pack |
|---|
| 30 tablet |
| Pack |
|---|
| 30 tablet |
| Pack |
|---|
| 30 tablet |
| Pack |
|---|
| 150 ml |
Relugolix for treating hormone-sensitive prostate cancer - NICE TA995
Relugolix is recommended, within its marketing authorisation, as an option for treating prostate cancer in adults:
-
with advanced hormone-sensitive prostate cancer
-
alongside radiotherapy for high-risk localised or locally advanced hormone-sensitive prostate cancer
-
as neoadjuvant treatment before radiotherapy for high-risk localised or locally advanced hormone-sensitive prostate cancer.
| Pack |
|---|
| 30 tablet |
- First Line Choice
- On Formulary
- Specialist Initiation Only
- Hospital Only
- KMPT Initiation Only